SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Diabetic weight loss medications are effective for people with schizophrenia without affecting psychotic symptoms, University ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support ...

1 Further, new data will complement the extensive body of cardiometabolic and kidney evidence for semaglutide in people with type 2 diabetes through analyses of the SOUL, STRIDE and FLOW trials ...